Product image of Nilho (Ethinylestradiol, Etonogestrel) supplied by GNH India

Nilho

Active Ingredient:
Ethinylestradiol, Etonogestrel
Origin:
EU

Nilho (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in Nilho, is a combined estrogen‑progestogen contraceptive presented as a vaginal contraceptive ring for vaginal use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus.

GNH India supplies Nilho as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratorios León Farma, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nilho, a combined estrogen‑progestogen contraceptive, is used within the hormonal contraception family to prevent unintended pregnancy.

  • Contraception: provides reliable, reversible prevention of pregnancy for women of child‑bearing potential.
  • Family planning: enables controlled fertility management in partnership with healthcare providers.
  • Ovulation suppression: inhibits gonadotropin release to stop the release of an egg each cycle.

How It Works

  • Ethinylestradiol and etonogestrel act together to suppress the hypothalamic‑pituitary‑ovarian axis, reducing the secretion of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). This inhibition prevents follicular development and ovulation. The progestogen component also thickens cervical mucus and induces endometrial changes that reduce the likelihood of implantation, providing multiple layers of contraceptive protection.

Side Effects

Common side effects are generally mild and transient, reflecting the hormonal activity of the ring.

Common Side Effects

  • Vaginal irritation or discharge: mild irritation at the insertion site.
  • Headache: occasional tension‑type headaches.
  • Nausea: mild stomach upset, often transient.
  • Breast tenderness: temporary swelling or soreness.
  • Mood changes: mild fluctuations in mood or irritability.
  • Spotting: irregular bleeding between periods.

Serious or Rare Side Effects

  • Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
  • Hepatic adenoma: rare benign liver tumor.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Hypertension: significant increase in blood pressure.
  • Visual disturbances: sudden loss of vision or blurred sight.
  • Ectopic pregnancy: implantation outside the uterus if contraception fails.

Precautions & Warnings

Before prescribing Nilho, clinicians should evaluate individual risk factors and counsel patients on proper use.

  • Assess thrombotic risk: review personal and family history of clotting disorders.
  • Screen for liver disease: avoid use in active hepatic impairment.
  • Evaluate cardiovascular status: consider hypertension or smoking history.
  • Counsel on smoking cessation: especially for women over 35 years.
  • Review medication history: identify drugs that may reduce efficacy.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and direct sunlight.

Avoid Interactions

Nilho may interact with other medicines that affect hormone metabolism or clotting pathways.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce contraceptive effectiveness.
  • Anticoagulants (e.g., warfarin): hormonal changes can alter INR stability.
  • Selective serotonin reuptake inhibitors (high dose): may increase risk of serotonin syndrome when combined with certain hormonal agents.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase hormone levels, raising side‑effect risk.
  • Certain antibiotics (e.g., tetracycline, metronidazole): may slightly diminish contraceptive efficacy.
  • Herbal supplements (e.g., St. John's wort): can modestly lower hormone concentrations.

Frequently Asked Questions

Nilho is a vaginal contraceptive ring that provides reversible hormonal birth control. It is prescribed to prevent unintended pregnancy in women of reproductive age by delivering a steady dose of ethinylestradiol and etonogestrel directly to the vaginal mucosa.

Ethinylestradiol, together with etonogestrel, suppresses the release of luteinizing hormone and follicle‑stimulating hormone from the pituitary gland. This inhibition stops ovulation, thickens cervical mucus, and alters the uterine lining, creating multiple barriers to fertilisation and implantation.

The dosing regimen for Nilho is determined by the prescribing clinician. Typically, a single vaginal ring is inserted and left in place for three weeks, followed by a one‑week ring‑free interval, but exact instructions must be confirmed with a healthcare professional.

Nilho is intended for use only when pregnancy is not desired. It should not be started during pregnancy, and if pregnancy occurs, the ring must be removed. Safety during breastfeeding has not been established; women should discuss alternatives with their provider.

To order Nilho, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral combined pills, Nilho delivers hormones locally via a vaginal ring, offering more stable serum levels and potentially fewer gastrointestinal side effects. Unlike transdermal patches, the ring requires less frequent handling and provides continuous dosing for three weeks.

Nilho should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Keep the product away from moisture, direct sunlight and extreme heat to maintain its integrity until the time of insertion.

A healthcare professional or the patient inserts the flexible vaginal ring into the upper vaginal fornix. The ring remains in place for three weeks, after which it is removed and discarded. A new ring is inserted after a one‑week ring‑free interval.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, hepatic adenoma, severe allergic reactions, and significant hypertension. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe abdominal pain, or signs of an allergic reaction.

Nilho is contraindicated in women with a history of thromboembolic disorders, active liver disease, known or suspected breast cancer, uncontrolled hypertension, or those who are pregnant. It should also be avoided by individuals who are hypersensitive to ethinylestradiol, etonogestrel, or any excipients in the ring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Etonogestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT